A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Trial Details

NCT ID
NCT07277413
Phase
PHASE1
Sponsor
IDEAYA Biosciences
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • IDE892
  • IDE397
Locations (sample)
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Coral Springs, Florida, United States|26.27119,-80.2706
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.
  • Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose e…
  • Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central co…
  • Must be willing and able to provide the blood/serum/plasma samples

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →